Abstract Lactoferrin possesses a wide range of immunomodulatory activities, including promotion of the delayed type hypersensitivity response (DTH) towards BCG (Bacillus Calmette Guerin) antigens. Addition of Lactoferrin as an adjuvant to the BCG vaccine was previously demonstrated to augment protection against subsequent mycobacterial challenge, with concomitant development of a strong T cell helper type 1 (T H 1) immunity. Because generation of T H 1 immunity is in large part dependent on the balance of monocytic pro-and anti-inXammatory cytokines, the eVect of Lactoferrin on leukocytes was investigated. Lactoferrin enhanced proinXammatory responses in a dose-dependant manner from splenocyte and adherent (F4/80 + ) splenocyte populations, bone marrow derived monocytes (BMM), and J774A.1 cultured cells. In all scenarios tested, Lactoferrin induced a strong increase in the ratio of IL-12:IL-10 production from LPS stimulated cells. Examination of Lactoferrin eVects on BCG infected J774A.1 cells and on BMM revealed similar immunomodulatory eVects, with particularly strong increase in IL-12 production. Furthermore, immunization of mice with BCG admixed with Lactoferrin led to increased generation of CD4+ cells expressing IFNupon restimulation with BCG antigens. These results provide molecular evidence to support the role of Lactoferrin as an adjuvant candidate to augment development of DTH response to vaccine antigens.
Introduction
Lactoferrin is an 80 kDa iron-binding protein belonging to the transferrin family of non-heme iron binding proteins, found primarily in mucosal secretions (e.g. milk) and secondary granules of neutrophils. Lactoferrin is an integral part of the innate immune system [30] , with immunomodulatory activities on leukocytes to increase phagocytic activity of neutrophils [32] , enhance activation of peritoneal macrophages [14] , increase natural killer cell activity [11, 41] , and promote maturation of T cells [12] and B cells [51] . Furthermore, Lactoferrin is capable of enhancing delayed type hypersensitivity (DTH) responses, as measured by foot pad swelling, to a variety of antigens, including sheep red blood cells (SRBC), ovalbumin (OVA), and Mycobacterium bovis Calmette Guerin (BCG) [8, 49, 50] . The generation of DTH, a T cell mediated response, against BCG with Lactoferrin suggests the ability of Lactoferrin to augment innate function to promote speciWc T cell responses against complex antigens.
BCG is the current vaccine for tuberculosis, a disease caused by the intracellular bacterium Mycobacterium tuberculosis (MTB). While BCG has been in use for nearly 85 years, the current vaccine has limited eYcacy in controlling MTB infection in adults [5, 16] ; there are only a small number of experimental vaccine alternatives that surpass the eYcacy of the existing BCG vaccine [6] . Successful control of MTB infection relies on mycobacterial antigen-speciWc cellular immunity; namely, a T cell dominated DTH response that is often characterized by high induction of IFN-, an indication of T cell helper type-1 (T H 1) activation [19] . Recently, Lactoferrin as an adjuvant was demonstrated to augment the BCG vaccine to protect against subsequent challenge with virulent MTB [25] , with increased IFNrecall response to BCG antigens. However, the molecular mechanisms underlying this observation were not deWned.
The generation of T H 1 immunity is dependent on professional antigen presenting cells (APC) such as macrophages, to produce IL-12, a mediator that promotes naïve T cell development towards the T H 1 phenotype [39, 40] . In addition, IL-12 is also a co-stimulator that can maximize secretion of IFN-from T H 1 cells [35] and activate IFNproducing cells from memory T cells [22] . Production of IL-12 is, in part, regulated by IL-10, which is produced by both macrophages and T cells. A high IL-10 level compared to IL-12 will lead to an environment that decreases promotion of T H 1 generation [17, 34] . Thus, a high IL-12:IL-10 ratio from activated macrophages is indicative of a cytokine environment that is favored towards promotion of T H 1 immunity. A limited number of studies have shown increasing IL-12 with concurrent decrease of IL-10 levels following administration of Lactoferrin [44, 46, 47] . Lactoferrin also demonstrated direct in vivo stimulatory activity in naïve mice with recovered peritoneal cells from mice injected with Lactoferrin exhibiting increased in TNF-, IL-6, and IL-12 production [1] . None of those studies speciWcally addressed how Lactoferrin functions as an adjuvant to augment subsequent adaptive responses.
The goal of these studies is to examine in vitro the eVect of bovine Lactoferrin on cytokine production from activated and non-activated leukocyte populations [42] , with focus on adjuvant activation to elicit cytokines that can drive T cell diVerentiation. The eVects of Lactoferrin will also be examined on BCG infected macrophages, monitoring the production of cytokine mediators that would promote the generation and stimulation of T cell immunity for use in future vaccination studies. In addition, immunization experiments were performed to examine Lactoferrin to promote generation of antigen-speciWc T H 1 responses from CD4+ T cells, as a functional in vivo endpoint for Lactoferrin mediation of response.
Materials and methods

Animals
Female C57BL/6 mice (6 weeks, Jackson Laboratories, Bar Harbor, ME) 20-25 g initial body weight, were used for splenocyte isolation, bone marrow derived monocyte generation, and immunization procedures. All in vivo experiments were conducted under approved guidelines of the animal ethics committee at the University of Texas, Health Science Center at Houston, protocol HSC-AWC-05-060.
Lactoferrin, LPS, BCG, and other reagents Low endotoxin bovine milk lactoferrin (<1 EU/mg, <20% iron saturated, >95% purity) was provided by PharmaReview Corporation (Houston, TX [7] . Single cell suspensions were cultured in DMEM complete base [Dulbecco's ModiWed Eagles Medium (DMEM, Sigma) with 2.2 g/L sodium bicarbonate (Sigma), 0.05 g/L HEPES (Sigma), and 0.05 g/ L L-arginine (Sigma)] supplemented with 10% fetal bovine serum (FBS, Sigma), antibiotics [100 g/mL penicillin G (Sigma) and 50 g/mL gentamycin sulfate (Sigma)], and 0.005% 2-mercaptoethanol (2Me, Gibco, Carlsbad, CA). Total splenocytes (2 £ 10 6 cells/mL) and adherent splenocytes (1 £ 10 6 cells/mL) were cultured with or without LPS (400 ng/mL). Increasing concentrations of Lactoferrin (1, 10, 100 g/mL) were added to splenocytes after 5 min with LPS (when indicated) and incubated at 37°C with 5% CO 2 for 48 h. Supernatants were collected and stored at ¡20°C for analysis by ELISA in triplicate. LPS dose response was performed to realize optimal versus suboptimal stimulation for all cell subsets and cell lines.
Bone marrow cells were isolated from C57BL/6 mice (6 weeks, Jackson Laboratories, Bar Harbor, ME) by Xushing the femur with McCoy's medium supplemented with antibiotics-100 g/mL penicillin G (Sigma) and 50 g/ mL gentamycin sulfate (Sigma). Collected cells were treated with ACK buVer (Cambrex Bio Sciences, East Rutherford, NJ) to lyse the red blood cells. Resulting cells were diVerentiated for 7 days at 1 £ 10 6 cells/mL in McCoy's medium, supplemented with 2.2 g/L sodium bicarbonate, 10% FBS, and GM-CSF (10 ng/mL) (Cell Sciences, Canton, MA). At day 7, non-adherent cells were washed oV and adherent cells (estimated at 5 £ 10 5 cells/ well) rested overnight in DMEM complete media-supplemented with 50 mg/L HEPES (Sigma), 50 mg/L L-arginine (Sigma), 2.2 g/L sodium bicarbonate (Sigma), and 10% FBS (Sigma)-at 37°C with 5% CO 2 . Macrophages remained non-infected or infected with BCG with and without Lactoferrin (100 g/mL). Supernatants were collected post-infection, and stored at ¡20°C for analysis by ELISA.
Murine-derived macrophage cell line J774A.1 was purchased from ATCC (#TIB-67). Macrophage cells were grown in DMEM complete base with 10% FBS. Macrophages were plated at 5 £ 10 5 cells/mL, rested for 4 h at 37 C with 5% CO 2 , then washed with 1£ PBS (Dulbecco's phosphate buVered saline 10£, Cellgro, Herndon, VA). Macrophages were cultured with or without LPS (1, 10 ng/ mL) in the absence or presence of increasing concentrations of Lactoferrin (1, 10, 100 g/mL), which was added 5 min after the addition of LPS (when indicated). Supernatants were collected at 24 and 72 h and stored at ¡20 C for analysis by ELISA in triplicate.
BCG infection
Infection with Mycobacterium bovis Calmette Guerin (BCG), Pasteur strain TMC 1011 was accomplished as reported previously [26] . BrieXy, organisms were grown in Dubos base (without addition of glycerol) with 10% supplement (5% BSA and 7.5% dextrose in saline) on an orbital shaker at 37 C for 2 weeks before use. Bacteria taken during log phase growth were resuspended in 1£ PBS, sonicated for 10 s to dislodge any clumping that might have occurred, and diluted to 3 £ 10 8 organisms/mL, estimated using McFarland Equivalence Turbidity Standards (Remel, Lenesa, KS). Cells were maintained at 37°C with 5% CO 2 in DMEM complete base supplemented with 10% FBS. Before use in infections, cells were adjusted to 5 £ 10 5 cells/mL in 24-well tissue culture plates. J774A.1 macrophages were infected with MOI (multiplicity of infection) of 10:1 (#organisms:#cells). Supernatants were collected after infection to assess cytokine production, measured by ELISA.
Enzyme linked immunosorbent assay (ELISA)
Supernatants were assayed for cytokine production using the DuoSet ELISA kits (R&D Systems, Minneapolis, MN), according to the manufacturer's instructions. BrieXy, the captured antibody was coated onto Costar EIA/RIA 1 £ 8 Stripwell™ plates (Corning Inc., Corning, NY) in 1£ PBS at 100 L/well and incubated at room temperature overnight. Plates were washed with wash buVer (0.05% v/v Tween 20 in 1£ PBS) three times (3£). Blocking buVer (1% w/v bovine serum albumin, BSA, 5% w/v sucrose, 0.05% w/v sodium azide in 1£ PBS) was added at 400 L/ well and incubated at room temperature for at least 1 h. After washing, isolated supernatants were loaded in triplicate at 100 L/well along with dilutions of cytokine standards and incubated at room temperature for 2 h. After washing, detection antibody diluted in manufacturer reagent diluent (R&D Systems, 1% BSA in 1£ PBS) was added at 100 L/well and incubated at room temperature for 2 h. Plates were washed and Streptavidin-HRP diluted at 1:200 was added at 100 L/well; the plate was further incubated at room temperature for 20 min away from direct light. SureBlue™ TMB microwell peroxidase substrate 1-component (KPL, Gaithersburg, MD) was added at 100 L/ well; 50 L/well of stop solution (2 N H 2 SO 4 ) was added after 30 min of dark incubation. Plates were read at 450 nm subtracting background at 570 nm. Concentration was calculated by generating a standard curve Wt. The following cytokines were measured by ELISA using triplicate wells; TNF-, IL-6, IL-12p40, IL-10 and IFN-. The lower assay limits of detection were approximately 15-25 pg/mL. Intracellular staining C57BL/6 mice remained non-immunized or were immunized and boosted at 2 weeks with BCG (1 £ 10 6 CFU/ mouse) or with BCG/Lactoferrin (100 g/mouse) in 1£ PBS subcutaneously (s.c.) at the base of the tail. At 8 weeks post-boost, splenocytes were examined for speciWc recall responses, as described with slight modiWcations [25, 45] . BrieXy, isolated splenocytes were cultured in DMEM complete medium supplemented with -Me, antibiotics, and IL-2 (100 ng/mL), and stimulated with heat-killed BCG (1:1 or 10:1). After 24 or 72 h, splenocytes were restimulated with ConA (2 g/mL) or with Ionomycin (250 ng/mL, Sigma) and phorbol 12-myristate 13-acetate (PMA, 10 ng/mL, Sigma) in the presence of golgi plug (BD Biosciences Pharmingen, San Diego, CA) for 4-6 h. Intracellular staining was conducted as per the manufacturer's instructions (BD). Non-speciWc surface antigens were blocked with CD16/CD32 Fc III/II receptor (1 g/1 £ 10 6 cells), and were then stained with CD4-FITC (1 g/1 £ 10 6 cells/ 50 L). Splenocytes were washed with staining buVer (1% BSA in 1£ PBS), then Wxed and permeablized with 250 L/sample BD CytoWx/Cytoperm. Cells were further stained with IFN--PE (0.5 g/1 £ 10 6 cells/50 L) and subsequent analysis was performed using Coulter Flow-Centre™ (EPICS XL-MCL). Results represent cells gated to exclued non-speciWc isotype matched control staining. Graphs were generated with WinMDI 2.8.
Statistical analysis
All experiments were completed at least three times with supernatants analyzed each time in triplicate. The Xow cytometric analysis was completed twice, using 4-6 mice per experiment. Average values and standard deviations of groups are shown. Statistical analysis was carried out using one way ANOVA; diVerences were considered signiWcant at P · 0.05.
Results
Lactoferrin aVects inXammatory and T H 1 mediators from LPS activated splenocytes
Previous studies on the in vivo eVect of Lactoferrin to modulate monocytic cytokine production examined cytokine production from isolated peritoneal cells. Mice treated with Lactoferrin yielded activated peritoneal cells with increased production of TNF-, IL-6 and IL-12 [1] . The immunomodulatory activities of Lactoferrin were further examined in vitro on murine splenocytes under activation by LPS.
Splenocytes were stimulated with LPS (400 ng/mL), a potent stimulant of macrophages involving TLR-4 and CD14 receptors. Increasing concentrations of Lactoferrin (1, 10, 100 g/mL) were added to LPS activated splenocytes or naïve splenocytes and monitored for production of inXammatory mediators, IL-12p40, IL-10, TNF-and IL-6 (Fig. 1) .
IL-12p40 production was slightly increased from splenocytes stimulated with LPS (81 § 10 pg/mL) compared to unstimulated splenocytes. Production of IL-12p40 from LPS stimulated splenocytes was further increased with the addition of Lactoferrin at 1 g/mL (94 § 13 pg/mL) and 10 g/mL (106 § 12 pg/mL). In contrast, there was a major reduction in IL-10 production from LPS stimulated splenocytes when Lactoferrin was added to the cultures. LPS stimulation alone enhance IL-10 production (104 § 13 pg/ mL) compared to the media control (19 § 2 pg/mL). The addition of Lactoferrin decreased splenic IL-10 production in a concentration-dependent manner: 10 g/mL (70 § 10 pg/mL) and 100 g/mL (36 § 8 pg/mL).
Addition of Lactoferrin (100 g/mL) to naïve splenocytes led to a slight, but signiWcant (P < 0.05) increase in TNF-production (54 § 28 pg/mL), and no signiWcant changes in IL-6, IL-12p40, or IL-10 production. LPS stimulated splenocytes increased production of TNF-(121 § 4 pg/mL), but no signiWcant changes were observed with the addition of Lactoferrin. Similarly, IL-6 production (µg/mL) (µg/mL) (µg/mL) (µg/mL) was increased with LPS stimulation (72 § 4 pg/mL), and no changes were observed with the addition of Lactoferrin.
The eVect of Lactoferrin on splenic populations was further investigated on adherent splenocytes enriched for cells expressing F4/80, a pan macrophage marker. The increased IL-12 was produced from this population. Comparison of the ratio of IL-12:IL-10 from LPS stimulated adherent splenocytes demonstrated that addition of Lactoferrin caused a modest but signiWcant (P < 0.05) increase in IL-12:10 ratios in a concentration-dependent manner (Table 1) .
Lactoferrin modulation of cytokine production from J774A.1 macrophage cells lines activated by LPS J774A.1 macrophages were stimulated with LPS at a suboptimal (1 ng/mL) or stimulatory (10 ng/mL) dose with or without increasing concentrations of Lactoferrin (1, 10, 100 g/mL). Lactoferrin alone only slightly aVected J774A.1 macrophages grown under normal conditions, with little change in IL-12p40 and IL-10 ( Fig. 2, top) , or TNF-and IL-6 (not shown), without further mitogenic stimulation. However, upon stimulation with LPS, Lactoferrin was able to mediate proinXammatory responses. Production of IL-12p40 and IL-10 were greatly aVected by Lactoferrin (Fig. 2, bottom) . Suboptimal dose of LPS (1 ng/ mL) stimulation generated production of IL-12p40 from J774A.1 macrophages at 24 h (266 § 31 pg/mL) and 72 h (224 § 6 pg/mL); addition of 100 g/mL of Lactoferrin further increased IL-12p40 production at 24 h (400 § 11 pg/mL) and 72 h (404 § 21 pg/mL). J774A.1 macrophages did not produce signiWcant levels of IL-10 without stimulation with LPS at the higher concentration (10 ng/mL). J774A.1 macrophages stimulated with 10 ng/ mL of LPS increased production IL-10 at 24 h (294 § 19 pg/mL). Addition of Lactoferrin to LPS (10 ng/ mL) stimulated J774A.1 macrophages decreased the production of IL-10 in a concentration-dependent manner: 1 g/mL (242 § 24 pg/mL), 10 g/mL (198 § 16 pg/mL), 100 g/mL (131 § 12 pg/mL). Overall, the ratio of production of IL-12:IL-10 was increased when cells were stimulated with LPS (1 and 10 ng/mL) in the presence of Lactoferrin at 72 h. A complete table of response is given in Table 2 (top, middle).
Table 1 Lactoferrin increases IL-12:10 ratio from LPS stimulated splenocytes
Splenocytes and F4/80+ enriched adherent cells from C57BL/6 mice were stimulated with LPS (400 ng/mL) with or without increasing concentrations of Lactoferrin (1, 10, 100 g/mL). Supernatants were collected and analyzed by ELISA. Concentrations of IL-12p40 were divided by IL-10. Average ratio with standard deviation shown for three experiments, each done in triplicate; * P < 0.05 relative to non-Lactoferrin treated controls At 72 h post stimulation, 100 g/mL of Lactoferrin signiWcantly elevated production of TNF-(167 § 18 pg/mL) compared to LPS alone (101 § 17 pg/mL). Similarly, IL-6 was further elevated with the addition of 100 g/mL of Lactoferrin (757 § 45 pg/mL), compared to LPS alone (634 § 15 pg/mL) (not shown).
Lactoferrin mediation of IL-12 and IL-10 production from BCG infected macrophages The activity of Lactoferrin was further examined on cytokine production from BCG infected macrophages. J774A.1 macrophages were infected with BCG at MOI of 10:1 with or without increasing concentrations of Lactoferrin (1, 10, 100 g/mL) (Fig. 3, top) . Bone marrow derived macrophages were examined using 100 g/mL Lactoferrin (Fig. 3,  bottom) . For both cell populations, IL-12p40 production from BCG infected cells was signiWcantly enhanced by the addition of Lactoferrin. By 72 h, BCG infected J774A.1 macrophages in the presence of Lactoferrin (100 g/mL) increased production of IL-12p40 in a concentration-dependent manner, with the highest IL-12p40 concentration observed at 100 g/mL of Lactoferrin (179 § 11 pg/mL), compared to non-Lactoferrin treated controls (116 § 9 pg/ mL). There was little to no production of IL-10 at any time point, regardless of infection status or addition of Lactoferrin. Examination of the ratio of production of IL-12:IL-10 from BCG infected macrophages (Table 2 , bottom) demonstrated similar properties as shown for cells stimulated with LPS; increasing concentrations of Lactoferrin led to increased IL-12:IL-10 ratios from infected cells. Similarly, the bone marrow derived macrophages were able to increase IL-12 production with concurrent reduction in IL-10 when Lactoferrin was added during BCG infection.
Immunization with BCG and Lactoferrin generates increased IFN-producing BCG antigen-speciWc CD4+ cells
The biological signiWcance of increased IL-12-IL-10 ratios was examined through immunization experiments to determine if immunization in the presence of Lactoferrin would alter numbers of CD4+ cells generated that produce IFNin speciWc response to BCG antigens. Mice were immunized with BCG, or BCG admixed with Lactoferrin (100 g/mL), and boosted after 2 weeks. Eight weeks later, recall responses to BCG antigens were examined. Both the BCG and the BCG/Lactoferrin immunized mice demonstrated high IFN-production (Fig. 4, top) compared to non-immunized control splenocytes. No signiWcant IL-4 production above that of the naïve control group was seen (not shown). Splenocyte populations were also subjected to analysis by Xow cytometry and intracellular staining (example for one animal shown in Fig 4, bottom) revealing signiWcantly increased numbers of CD4+ cells producing IFN-in the Lactoferrin adjuvant group in response to antigenic stimulation (group average,18.36% § 0.67) Table 2 Lactoferrin induces an increase in IL-12:IL-10 ratio from LPS-stimulated or BCG infected macrophages J774A.1 macrophages were stimulated with 1 ng/mL LPS (top) or 10 ng/mL LPS (middle) with or without increasing concentrations of Lactoferrin (1, 10, 100 g/mL). Alternatively, cells were infected with BCG (MOI 10:1) (bottom) with or without Lactoferrin. Supernatants were collected at 72 h and analyzed by ELISA. Ratio was calculated by dividing concentration of IL-12p40 by IL-10. * P < 0.05 relative to non-Lactoferrin treated controls compared to BCG alone immunized cells (group average, 11.99% § 2.93) (P < 0.05). These experiments demonstrate that Lactoferrin included in the vaccination formulation was capable of augmenting the generation of antigenspeciWc CD4+ T H 1 phenotypic cells.
Discussion
Lactoferrin is an integral part of the innate immune system [30] which is recognized as an immunomodulator of leukocyte populations, including neutrophils [32] , peritoneal macrophages [14] , natural killer cells [11, 41] , T cells [12] , and B cells [51] . More importantly, Lactoferrin as an adjuvant is capable of enhancing the T cell mediated DTH response to a variety of antigens including Mycobacterium bovis Calmette Guerin (BCG) [27, 49, 50] . The primary goal of these studies was to examine, in vitro, the eVect of bovine Lactoferrin on cytokine production from activated and non-activated leukocyte populations [42] , with focus on deWning responsive phenotypes and identifying cytokines that can drive T cell diVerentiation, in particular IL-12 and IL-10. The secondary goal was to establish that Lactoferrin administered with a complex vaccine antigen would result in increased production of CD4+ T helper antigen-speciWc responses, a subject under active investigation [18] .
Receptors for Lactoferrin are present on both lymphocytes and macrophages [43] , thus evaluation of Lactoferrin activity was initially examined on splenocyte. Whole splenocytes stimulated with LPS in the presence of Lactoferrin increased the ratio of IL-12:IL-10 production. The activity was found in adherent splenocytes enriched for F4/ 80 + (a pan macrophage marker) cells, suggesting that the cell population responding to LPS and Lactoferrin stimulation was macrophages. Indeed, direct stimulation of CD3+ lymphocytes by Lactoferrin does not occur (unpublished observations). Addition of Lactoferrin to naïve macrophages increased TNF-production, a stimulatory eVect that has also been reported elsewhere [42] . The eVect of Lactoferrin on activated macrophages is a more complex phenomenon. Addition of Lactoferrin to macrophages stimulated with suboptimal LPS (1 ng/mL) increased production of IL-12 and decreased production of IL-10. This stimulatory activity may be attributed to Lactoferrin forming a complex with LPS to facilitate macrophage activation through CD14 (LPS co-stimulatory molecule) or the TLR-4 (LPS receptor) [36] . Previous studies on LPS activated macrophages and models of sepsis also reported this inhibitory eVect of Lactoferrin to moderate other proinXammatory mediators [9, 37] . Certainly, the ability of Lactoferrin to inhibit LPS-induced production of TNF-and IL-6 is present when Lactoferrin is administered prophylactically (and even therapeutically) [29] , or even when given therapeutically. The anti-inXammatory eVects of Lactoferrin may simply be attributed to its ability to disrupt LPS binding of CD14 [3, 15] . Other studies indicate that Lactoferrin's anti-inXammatory eVect may be more complex, and is regulated through modulation of nitric oxide mediators [28] . Of interest to this report, Lactoferrin decreased inXammatory responses while increasing macrophage mediators to potentially direct development of T H 1 immunity.
Increasing IL-12 is an important step in directing development of the T H 1 response [39, 40] , critical for protection against MTB infection [10, 21] . Lactoferrin-induced increased relative IL-12 would address the mechanisms by which Lactoferrin acts as an adjuvant to augment BCG vaccine eYcacy against subsequent mycobacterial challenge [25] . In the studies outlined here, addition of Lactoferrin to BCG infected macrophages enhanced the IL-12:IL-10 ratio, with J774A.1 macrophages and BMM infected with BCG producing signiWcant amounts of IL-12. More critical was the Wnding that immunization in the presence of Lactoferrin led to antigen-speciWc responses to BCG that were of the T H 1 phenotype. The increased IFN-production was further identiWed as derived in large part from CD4+ T cells, thus indicating a functional link to observations seen in the tissue culture experiments. At this time, it is unknown how Lactoferrin causes macrophages to inXuence T cell responses in vivo. It may be that Lactoferrin functions through modiWcation of proinXammatory response aVecting how macrophages communicate with other cells in a local environment. Just as likely, Lactoferrin may modify surface molecule expression on APC, allowing for direct regulation of responding lymphocytes. These areas require further research.
Lactoferrin can also increase production of TNF-and IL-6 from stimulated macrophages. During MTB infection, TNF-and IL-6 work in concert to initiate and inXuence the development of the granulomatous response, an organization of cellular inWltrate at the site of infection important in containment of bacteria [2, 4, 20, 33, 38] . However, TNF-and IL-6 are also involved in directing the generation of the T H 1 response, but unlike IL-12, they are indirectly involved in suppressing T H 1 responses. TNFinhibits IL-12 and the subsequent production of IFN-, limiting IL-12 through both IL-10 dependent and independent means [23, 31, 48] . IL-6 suppresses T H 1 development by boosting the T H 2 activity of IL-4 and interfering with IFNsignaling [13] , and redirecting T helper responses [24] . At this time, the role for Lactoferrin in modifying TNF-and IL-6 production in infected cells is less clear.
The experiments presented here suggested that Lactoferrin modulates the cytokine environment of LPS stimulated and BCG infected macrophages to allow, potentially, promotion of a substantial T H 1 development, in vivo. It also suggests that the activity of Lactoferrin is dependent on the activation status of the macrophage. The direct molecular mechanisms for Lactoferrin mediation of immune activation and cytokine production still remain unresolved. However, the results from this report identify Lactoferrin as an ideal adjuvant candidate, and provide one possible molecular explanation to support its use to boost eYcacy of the BCG vaccine to promote host protective responses during virulent MTB infection.
